Shanghai – September 25, 2026 -- IASO Biotechnology reported an 88.9% objective response rate for its dual-targeted CAR-T therapy RD140 in a first-in-human Phase 1 trial of nine heavily pretreated multiple myeloma and plasma cell leukemia patients, with the response rate reaching 100% in the higher-dose cohort.